Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:EGFR-INSL4 (FusionGDB2 ID:25438)

Fusion Gene Summary for EGFR-INSL4

Fusion gene summary

Fusion gene information	Fusion gene name: EGFR-INSL4
	Fusion gene ID: 25438
		Hgene	Tgene
	Gene symbol	EGFR	INSL4
	Gene ID	1956	3641
	Gene name	epidermal growth factor receptor	insulin like 4
	Synonyms	ERBB\|ERBB1\|HER1\|NISBD2\|PIG61\|mENA	EPIL\|PLACENTIN
	Cytomap	7p11.2	9p24.1
	Type of gene	protein-coding	protein-coding
	Description	epidermal growth factor receptoravian erythroblastic leukemia viral (v-erb-b) oncogene homologcell growth inhibiting protein 40cell proliferation-inducing protein 61epidermal growth factor receptor tyrosine kinase domainerb-b2 receptor tyrosine kinas	early placenta insulin-like peptideearly placenta insulin-like peptide (EPIL)insulin-like 4 (placenta)insulin-like peptide 4
	Modification date	20200329	20200313
	UniProtAcc	P00533	.
	Ensembl transtripts involved in fusion gene	ENST00000455089, ENST00000342916, ENST00000344576, ENST00000420316, ENST00000275493, ENST00000442591, ENST00000463948, ENST00000454757,	ENST00000239316,
Fusion gene scores	* DoF score	41 X 25 X 14=14350	3 X 2 X 3=18
	# samples	53	4
	** MAII score	log2(53/14350*10)=-4.75891456699985 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(4/18*10)=1.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Context	PubMed: EGFR [Title/Abstract] AND INSL4 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	EGFR(55087058)-INSL4(5233654), # samples:2
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	EGFR	GO:0001934	positive regulation of protein phosphorylation	20551055
Hgene	EGFR	GO:0007165	signal transduction	10572067
Hgene	EGFR	GO:0007166	cell surface receptor signaling pathway	7736574
Hgene	EGFR	GO:0007173	epidermal growth factor receptor signaling pathway	7736574\|12435727
Hgene	EGFR	GO:0008283	cell proliferation	17115032
Hgene	EGFR	GO:0008284	positive regulation of cell proliferation	7736574
Hgene	EGFR	GO:0010750	positive regulation of nitric oxide mediated signal transduction	12828935
Hgene	EGFR	GO:0018108	peptidyl-tyrosine phosphorylation	22732145
Hgene	EGFR	GO:0030307	positive regulation of cell growth	15467833
Hgene	EGFR	GO:0042177	negative regulation of protein catabolic process	17115032
Hgene	EGFR	GO:0042327	positive regulation of phosphorylation	15082764
Hgene	EGFR	GO:0043406	positive regulation of MAP kinase activity	10572067
Hgene	EGFR	GO:0045739	positive regulation of DNA repair	17115032
Hgene	EGFR	GO:0045740	positive regulation of DNA replication	17115032
Hgene	EGFR	GO:0045944	positive regulation of transcription by RNA polymerase II	20551055
Hgene	EGFR	GO:0050679	positive regulation of epithelial cell proliferation	10572067
Hgene	EGFR	GO:0050999	regulation of nitric-oxide synthase activity	12828935
Hgene	EGFR	GO:0070141	response to UV-A	18483258
Hgene	EGFR	GO:0070374	positive regulation of ERK1 and ERK2 cascade	20551055
Hgene	EGFR	GO:0071392	cellular response to estradiol stimulus	20551055
Hgene	EGFR	GO:1900020	positive regulation of protein kinase C activity	22732145
Hgene	EGFR	GO:1903078	positive regulation of protein localization to plasma membrane	22732145

Fusion gene breakpoints across EGFR (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across INSL4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	STAD	TCGA-BR-6706-01A	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
ChimerDB4	STAD	TCGA-BR-6706-01A	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+

Top

Fusion Gene ORF analysis for EGFR-INSL4

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
In-frame	ENST00000455089	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
In-frame	ENST00000342916	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
In-frame	ENST00000344576	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
In-frame	ENST00000420316	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
In-frame	ENST00000275493	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
In-frame	ENST00000442591	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
3UTR-3CDS	ENST00000463948	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+
intron-3CDS	ENST00000454757	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000455089	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1996	345	398	0	133
ENST00000342916	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1985	334	472	83	129
ENST00000344576	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1984	333	471	82	129
ENST00000420316	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1983	332	470	81	129
ENST00000275493	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1916	265	403	14	129
ENST00000442591	EGFR	chr7	55087058	+	ENST00000239316	INSL4	chr9	5233654	+	1899	248	386	0	129

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000455089	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.044436697	0.95556325
ENST00000342916	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.040829748	0.9591703
ENST00000344576	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.044101942	0.9558981
ENST00000420316	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.036607247	0.9633928
ENST00000275493	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.025662336	0.9743377
ENST00000442591	ENST00000239316	EGFR	chr7	55087058	+	INSL4	chr9	5233654	+	0.021379769	0.9786202

Top

Fusion Genomic Features for EGFR-INSL4

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	1-p	p (fusion gene breakpoint)
EGFR	chr7	55087058	+	INSL4	chr9	5233653	+	0.000744206	0.9992557
EGFR	chr7	55087058	+	INSL4	chr9	5233653	+	0.000744206	0.9992557

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for EGFR-INSL4

Go to
FGviewer for the breakpoints of chr7:55087058-chr9:5233654
.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
EGFR P00533	.
FUNCTION: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250\|UniProtKB:Q01279, ECO:0000269\|PubMed:10805725, ECO:0000269\|PubMed:11116146, ECO:0000269\|PubMed:11483589, ECO:0000269\|PubMed:11602604, ECO:0000269\|PubMed:12297049, ECO:0000269\|PubMed:12297050, ECO:0000269\|PubMed:12620237, ECO:0000269\|PubMed:12873986, ECO:0000269\|PubMed:15374980, ECO:0000269\|PubMed:15590694, ECO:0000269\|PubMed:15611079, ECO:0000269\|PubMed:17115032, ECO:0000269\|PubMed:17909029, ECO:0000269\|PubMed:19560417, ECO:0000269\|PubMed:20462955, ECO:0000269\|PubMed:20837704, ECO:0000269\|PubMed:21258366, ECO:0000269\|PubMed:27153536, ECO:0000269\|PubMed:2790960, ECO:0000269\|PubMed:7679104, ECO:0000269\|PubMed:8144591, ECO:0000269\|PubMed:9419975}.; FUNCTION: Isoform 2 may act as an antagonist of EGF action.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269\|PubMed:21516087}.	FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

712_979

29.333333333333332

1211.0

Domain

Protein kinase

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

712_979

29.333333333333332

629.0

Domain

Protein kinase

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

712_979

29.333333333333332

706.0

Domain

Protein kinase

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

712_979

29.333333333333332

406.0

Domain

Protein kinase

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

718_726

29.333333333333332

1211.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

790_791

29.333333333333332

1211.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

718_726

29.333333333333332

629.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

790_791

29.333333333333332

629.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

718_726

29.333333333333332

706.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

790_791

29.333333333333332

706.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

718_726

29.333333333333332

406.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

790_791

29.333333333333332

406.0

Nucleotide binding

ATP

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

688_704

29.333333333333332

1211.0

Region

Note=Important for dimerization%2C phosphorylation and activation

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

688_704

29.333333333333332

629.0

Region

Note=Important for dimerization%2C phosphorylation and activation

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

688_704

29.333333333333332

706.0

Region

Note=Important for dimerization%2C phosphorylation and activation

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

688_704

29.333333333333332

406.0

Region

Note=Important for dimerization%2C phosphorylation and activation

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

390_600

29.333333333333332

1211.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

75_300

29.333333333333332

1211.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

390_600

29.333333333333332

629.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

75_300

29.333333333333332

629.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

390_600

29.333333333333332

706.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

75_300

29.333333333333332

706.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

390_600

29.333333333333332

406.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

75_300

29.333333333333332

406.0

Repeat

Note=Approximate

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

25_645

29.333333333333332

1211.0

Topological domain

Extracellular

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

669_1210

29.333333333333332

1211.0

Topological domain

Cytoplasmic

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

25_645

29.333333333333332

629.0

Topological domain

Extracellular

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

669_1210

29.333333333333332

629.0

Topological domain

Cytoplasmic

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

25_645

29.333333333333332

706.0

Topological domain

Extracellular

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

669_1210

29.333333333333332

706.0

Topological domain

Cytoplasmic

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

25_645

29.333333333333332

406.0

Topological domain

Extracellular

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

669_1210

29.333333333333332

406.0

Topological domain

Cytoplasmic

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000275493

646_668

29.333333333333332

1211.0

Transmembrane

Helical

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000342916

646_668

29.333333333333332

629.0

Transmembrane

Helical

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000344576

646_668

29.333333333333332

706.0

Transmembrane

Helical

Hgene

EGFR

chr7:55087058

chr9:5233654

ENST00000420316

646_668

29.333333333333332

406.0

Transmembrane

Helical

Top

Fusion Gene Sequence for EGFR-INSL4

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>In-frame_ENST00000455089_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1996nt_BP=345nt
GTCCGGGCAGCCCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCC
CGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCC
ACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCG
GGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATGGTGTCAACCT
CCAACAACAAAGATGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTGTCTGAAGGGC
AGCCATCATTGAAGAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTAATTTGTGACG
ATGGAACTTCAGTTAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAATGACAAATTCA
CTGATGCCCAATTAAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTACTAATATAGTC
TCTCCAAATGGAGGAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAATTCACTGTAT
ATTCCAAAATAGCTAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTACCCTGATTTG
ATCATTACACATTATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAACTTACTGGAA
ATAAATTTTTAAAGTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCACACTAGAAGA
AATGTAAGAGATAAAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTGGGAGAGGTAT
TAGGCATGTTCACCCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCACGCTGCCTTT
AGACCTTCAATCATTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCACAAATACTGGC
ATTCCTCTGGCTACACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGAGGTTCTACTA
GTTGTGTTTGTTTGTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCATGATTTGAGTA
GCCCCCTGTGCCTGCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACTTGTAGGTCAT
CATAGAGACTGTAATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGTGTAGGTAAGA
GGAGAGAGCAAAATTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAAGGGACAAGTA
GAAGCCCAGGAAAATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGTGGAGAAAAGG
AATTGTCAAGATCTGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGCTGCATCCTGG

>In-frame_ENST00000455089_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=133AA_start in transcript=398_stop in transcript=0
MMSYLRLVHLCCWRLTPFLSFPPEPDSPGRAQPAAPGALPRPSRRVASLLPEELAPALPINTGRSQGAVRGGCGVGGEAGTRADADEVAC

--------------------------------------------------------------
>In-frame_ENST00000342916_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1985nt_BP=334nt
CCCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCC
CGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGC
GCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGG
GCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATGGTGTCAACCTCCAACAACAAA
GATGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTGTCTGAAGGGCAGCCATCATTG
AAGAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTAATTTGTGACGATGGAACTTCA
GTTAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAATGACAAATTCACTGATGCCCAA
TTAAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTACTAATATAGTCTCTCCAAATGG
AGGAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAATTCACTGTATATTCCAAAATA
GCTAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTACCCTGATTTGATCATTACACA
TTATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAACTTACTGGAAATAAATTTTTA
AAGTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCACACTAGAAGAAATGTAAGAGA
TAAAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTGGGAGAGGTATTAGGCATGTTC
ACCCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCACGCTGCCTTTAGACCTTCAAT
CATTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCACAAATACTGGCATTCCTCTGGC
TACACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGAGGTTCTACTAGTTGTGTTTGT
TTGTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCATGATTTGAGTAGCCCCCTGTGC
CTGCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACTTGTAGGTCATCATAGAGACTG
TAATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGTGTAGGTAAGAGGAGAGAGCAA
AATTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAAGGGACAAGTAGAAGCCCAGGA
AAATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGTGGAGAAAAGGAATTGTCAAGA
TCTGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGCTGCATCCTGGAGTAAGGAAGA

>In-frame_ENST00000342916_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=129AA_start in transcript=472_stop in transcript=83
MRESIIFFNDGCPSDSGFFSSGDKLGMNSDVVPKACPSLLLEVDTISFFSSRARLAGQSAASSARSAAPAVPEGRIAAPRRARSGSPDQY

--------------------------------------------------------------
>In-frame_ENST00000344576_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1984nt_BP=333nt
CCCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCC
GGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGCG
CACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGGG
CAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATGGTGTCAACCTCCAACAACAAAG
ATGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTGTCTGAAGGGCAGCCATCATTGA
AGAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTAATTTGTGACGATGGAACTTCAG
TTAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAATGACAAATTCACTGATGCCCAAT
TAAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTACTAATATAGTCTCTCCAAATGGA
GGAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAATTCACTGTATATTCCAAAATAG
CTAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTACCCTGATTTGATCATTACACAT
TATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAACTTACTGGAAATAAATTTTTAA
AGTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCACACTAGAAGAAATGTAAGAGAT
AAAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTGGGAGAGGTATTAGGCATGTTCA
CCCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCACGCTGCCTTTAGACCTTCAATC
ATTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCACAAATACTGGCATTCCTCTGGCT
ACACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGAGGTTCTACTAGTTGTGTTTGTT
TGTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCATGATTTGAGTAGCCCCCTGTGCC
TGCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACTTGTAGGTCATCATAGAGACTGT
AATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGTGTAGGTAAGAGGAGAGAGCAAA
ATTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAAGGGACAAGTAGAAGCCCAGGAA
AATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGTGGAGAAAAGGAATTGTCAAGAT
CTGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGCTGCATCCTGGAGTAAGGAAGAA

>In-frame_ENST00000344576_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=129AA_start in transcript=471_stop in transcript=82
MRESIIFFNDGCPSDSGFFSSGDKLGMNSDVVPKACPSLLLEVDTISFFSSRARLAGQSAASSARSAAPAVPEGRIAAPRRARSGSPDQY

--------------------------------------------------------------
>In-frame_ENST00000420316_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1983nt_BP=332nt
CCGGCGCAGCGCGGCCGCAGCAGCCTCCGCCCCCCGCACGGTGTGAGCGCCCGACGCGGCCGAGGCGGCCGGAGTCCCGAGCTAGCCCCG
GCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCACCGCGC
ACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGCCGGGGC
AGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATGGTGTCAACCTCCAACAACAAAGA
TGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTGTCTGAAGGGCAGCCATCATTGAA
GAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTAATTTGTGACGATGGAACTTCAGT
TAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAATGACAAATTCACTGATGCCCAATT
AAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTACTAATATAGTCTCTCCAAATGGAG
GAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAATTCACTGTATATTCCAAAATAGC
TAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTACCCTGATTTGATCATTACACATT
ATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAACTTACTGGAAATAAATTTTTAAA
GTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCACACTAGAAGAAATGTAAGAGATA
AAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTGGGAGAGGTATTAGGCATGTTCAC
CCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCACGCTGCCTTTAGACCTTCAATCA
TTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCACAAATACTGGCATTCCTCTGGCTA
CACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGAGGTTCTACTAGTTGTGTTTGTTT
GTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCATGATTTGAGTAGCCCCCTGTGCCT
GCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACTTGTAGGTCATCATAGAGACTGTA
ATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGTGTAGGTAAGAGGAGAGAGCAAAA
TTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAAGGGACAAGTAGAAGCCCAGGAAA
ATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGTGGAGAAAAGGAATTGTCAAGATC
TGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGCTGCATCCTGGAGTAAGGAAGAAC

>In-frame_ENST00000420316_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=129AA_start in transcript=470_stop in transcript=81
MRESIIFFNDGCPSDSGFFSSGDKLGMNSDVVPKACPSLLLEVDTISFFSSRARLAGQSAASSARSAAPAVPEGRIAAPRRARSGSPDQY

--------------------------------------------------------------
>In-frame_ENST00000275493_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1916nt_BP=265nt
GCCGGAGTCCCGAGCTAGCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGC
CGCCAACGCCACAACCACCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATG
CGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATG
GTGTCAACCTCCAACAACAAAGATGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTG
TCTGAAGGGCAGCCATCATTGAAGAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTA
ATTTGTGACGATGGAACTTCAGTTAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAAT
GACAAATTCACTGATGCCCAATTAAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTAC
TAATATAGTCTCTCCAAATGGAGGAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAA
TTCACTGTATATTCCAAAATAGCTAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTA
CCCTGATTTGATCATTACACATTATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAA
CTTACTGGAAATAAATTTTTAAAGTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCA
CACTAGAAGAAATGTAAGAGATAAAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTG
GGAGAGGTATTAGGCATGTTCACCCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCA
CGCTGCCTTTAGACCTTCAATCATTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCAC
AAATACTGGCATTCCTCTGGCTACACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGA
GGTTCTACTAGTTGTGTTTGTTTGTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCAT
GATTTGAGTAGCCCCCTGTGCCTGCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACT
TGTAGGTCATCATAGAGACTGTAATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGT
GTAGGTAAGAGGAGAGAGCAAAATTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAA
GGGACAAGTAGAAGCCCAGGAAAATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGT
GGAGAAAAGGAATTGTCAAGATCTGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGC

>In-frame_ENST00000275493_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=129AA_start in transcript=403_stop in transcript=14
MRESIIFFNDGCPSDSGFFSSGDKLGMNSDVVPKACPSLLLEVDTISFFSSRARLAGQSAASSARSAAPAVPEGRIAAPRRARSGSPDQY

--------------------------------------------------------------
>In-frame_ENST00000442591_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(transcript)=1899nt_BP=248nt
GCCCCGGCGGCCGCCGCCGCCCAGACCGGACGACAGGCCACCTCGTCGGCGTCCGCCCGAGTCCCCGCCTCGCCGCCAACGCCACAACCA
CCGCGCACGGCCCCCTGACTCCGTCCAGTATTGATCGGGAGAGCCGGAGCGAGCTCTTCGGGGAGCAGCGATGCGACCCTCCGGGACGGC
CGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGAAATGGTGTCAACCTCCAACAA
CAAAGATGGACAAGCCTTAGGTACGACATCAGAATTCATTCCTAATTTGTCACCAGAGCTGAAGAAACCACTGTCTGAAGGGCAGCCATC
ATTGAAGAAAATAATACTTTCCCGCAAAAAGAGAAGTGGACGTCACAGATTTGATCCATTCTGTTGTGAAGTAATTTGTGACGATGGAAC
TTCAGTTAAATTATGTACATAGTAGAGTAATCATGGACTGGACATCTCATCCATTCTCATATGTATTCTCAATGACAAATTCACTGATGC
CCAATTAAATGATTGCTGTTTATTAGAACATGAGAATCATTATTAGTATTCACATGTTTCACTTGCTCTGTACTAATATAGTCTCTCCAA
ATGGAGGAAGTTAGATAGATGGAATAAGTTCTAGTAGTTGATAGTACAATGGGGAAATTATACTTAACAATAATTCACTGTATATTCCAA
AATAGCTAGAAGAGAATTGTAATGATTCCAACACAAAAAAGATGAATGTTAGTTTGGATGCATATCCCAATTACCCTGATTTGATCATTA
CACATTATATACACGTATCAAAATATCACATGTACTACAAAAATGTGTATAACTGTAATATGTGAACTACAAACTTACTGGAAATAAATT
TTTAAAGTTTTACACACATAAACACATACGTTCACACACACTCACTCAAGTCTCTTCATTTTTCCTCTTTTCACACTAGAAGAAATGTAA
GAGATAAAGGATCTAACCATCTCTAACATCAGCTCATAGTACGGAGGAAAAGCAGTGAAGGAATGAACTGGTGGGAGAGGTATTAGGCAT
GTTCACCCTAGGGTAAACCCAGAGACCTCCCTAGAACTTTGCCCAATGCATATCCTCCACCTGCCTCTCAGCACGCTGCCTTTAGACCTT
CAATCATTCTATAAACTCCTCTTTTGTCCCTGGCATTACTCCACATCCCCTCATCAAAGTGGTGAATTGGCACAAATACTGGCATTCCTC
TGGCTACACATACCTCCTCCCTATGTGTCTCTAAATCCTAAATCAAAGAGTACATTTTATACTCTGTCAGTGAGGTTCTACTAGTTGTGT
TTGTTTGTTTGCAGGCTAACTGAAGCTGCTACTACCTCATTATCAGGTCCTATAAACTTAATTCAAGTGGCATGATTTGAGTAGCCCCCT
GTGCCTGCCCATAAAGTGCTCTGAATCTAGTGTGGGACATGGAGAAGCAAAGGATAATAAGTGCAATGATACTTGTAGGTCATCATAGAG
ACTGTAATGATCCACAGGAATCAGGGTCGTGTTTAATGCCAACATGTGAAAGAATAAATATACAGGGAACAGTGTAGGTAAGAGGAGAGA
GCAAAATTTCCCTAAGGAAACTGATGGCTGATCTGCATCTTGAAAGACATCTAAGCAGAAGAGAGTGCAAAAAGGGACAAGTAGAAGCCC
AGGAAAATGCACAAAGGCCTGGAAGCATAGCATGTGTGGAAACAGCCAGAGTCAGCAGGGCAGGAGGTGGTGTGGAGAAAAGGAATTGTC
AAGATCTGGTTGGAATGGAGACAGGAGAGAGGATCTCAAACGATTCCACACAATGCAGCTATGGGGTTTAGGCTGCATCCTGGAGTAAGG

>In-frame_ENST00000442591_ENST00000239316_TCGA-BR-6706-01A_EGFR_chr7_55087058_+_INSL4_chr9_5233654_length(amino acids)=129AA_start in transcript=386_stop in transcript=0
MRESIIFFNDGCPSDSGFFSSGDKLGMNSDVVPKACPSLLLEVDTISFFSSRARLAGQSAASSARSAAPAVPEGRIAAPRRARSGSPDQY

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for EGFR-INSL4

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for EGFR-INSL4

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner	Gene	UniProtAcc	DrugBank ID	Drug name	Drug activity	Drug type	Drug status
Hgene	EGFR	P00533	DB00002	Cetuximab	Antagonist	Biotech	Approved
Hgene	EGFR	P00533	DB00002	Cetuximab	Antagonist	Biotech	Approved
Hgene	EGFR	P00533	DB00002	Cetuximab	Antagonist	Biotech	Approved
Hgene	EGFR	P00533	DB00002	Cetuximab	Antagonist	Biotech	Approved
Hgene	EGFR	P00533	DB05294	Vandetanib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB05294	Vandetanib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB05294	Vandetanib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB05294	Vandetanib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB08916	Afatinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB08916	Afatinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB08916	Afatinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB08916	Afatinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB09330	Osimertinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB09330	Osimertinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB09330	Osimertinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB09330	Osimertinib	Inhibitor	Small molecule	Approved
Hgene	EGFR	P00533	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	EGFR	P00533	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	EGFR	P00533	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	EGFR	P00533	DB10772	Foreskin keratinocyte (neonatal)	Agonist	Biotech	Approved
Hgene	EGFR	P00533	DB00317	Gefitinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00317	Gefitinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00317	Gefitinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00317	Gefitinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00530	Erlotinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00530	Erlotinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00530	Erlotinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00530	Erlotinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB01259	Lapatinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB01259	Lapatinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB01259	Lapatinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB01259	Lapatinib	Antagonist	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB01269	Panitumumab	Suppressor	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB01269	Panitumumab	Suppressor	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB01269	Panitumumab	Suppressor	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB01269	Panitumumab	Suppressor	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB09559	Necitumumab	Antagonist	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB09559	Necitumumab	Antagonist	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB09559	Necitumumab	Antagonist	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB09559	Necitumumab	Antagonist	Biotech	Approved\|Investigational
Hgene	EGFR	P00533	DB11828	Neratinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11828	Neratinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11828	Neratinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11828	Neratinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11963	Dacomitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11963	Dacomitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11963	Dacomitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB11963	Dacomitinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12010	Fostamatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12267	Brigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12267	Brigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12267	Brigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB12267	Brigatinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB15035	Zanubrutinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB15035	Zanubrutinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB15035	Zanubrutinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB15035	Zanubrutinib	Inhibitor	Small molecule	Approved\|Investigational
Hgene	EGFR	P00533	DB00281	Lidocaine	Antagonist	Small molecule	Approved\|Vet_approved
Hgene	EGFR	P00533	DB00281	Lidocaine	Antagonist	Small molecule	Approved\|Vet_approved
Hgene	EGFR	P00533	DB00281	Lidocaine	Antagonist	Small molecule	Approved\|Vet_approved
Hgene	EGFR	P00533	DB00281	Lidocaine	Antagonist	Small molecule	Approved\|Vet_approved

Top

Related Diseases for EGFR-INSL4

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	EGFR	C0007131	Non-Small Cell Lung Carcinoma	16	CGI;CTD_human
Hgene	EGFR	C0024121	Lung Neoplasms	7	CGI;CTD_human
Hgene	EGFR	C0242379	Malignant neoplasm of lung	7	CGI;CTD_human
Hgene	EGFR	C0006142	Malignant neoplasm of breast	6	CTD_human
Hgene	EGFR	C0678222	Breast Carcinoma	6	CTD_human
Hgene	EGFR	C1257931	Mammary Neoplasms, Human	6	CTD_human
Hgene	EGFR	C1458155	Mammary Neoplasms	6	CTD_human
Hgene	EGFR	C4704874	Mammary Carcinoma, Human	6	CTD_human
Hgene	EGFR	C0001418	Adenocarcinoma	5	CTD_human
Hgene	EGFR	C0205641	Adenocarcinoma, Basal Cell	5	CTD_human
Hgene	EGFR	C0205642	Adenocarcinoma, Oxyphilic	5	CTD_human
Hgene	EGFR	C0205643	Carcinoma, Cribriform	5	CTD_human
Hgene	EGFR	C0205644	Carcinoma, Granular Cell	5	CTD_human
Hgene	EGFR	C0205645	Adenocarcinoma, Tubular	5	CTD_human
Hgene	EGFR	C0334588	Giant Cell Glioblastoma	5	CTD_human;ORPHANET
Hgene	EGFR	C0007137	Squamous cell carcinoma	3	CTD_human
Hgene	EGFR	C0007873	Uterine Cervical Neoplasm	3	CTD_human
Hgene	EGFR	C0014859	Esophageal Neoplasms	3	CGI;CTD_human
Hgene	EGFR	C0017636	Glioblastoma	3	CGI;CTD_human
Hgene	EGFR	C0018671	Head and Neck Neoplasms	3	CGI;CTD_human
Hgene	EGFR	C0018675	Head Neoplasms	3	CTD_human
Hgene	EGFR	C0024623	Malignant neoplasm of stomach	3	CTD_human
Hgene	EGFR	C0027533	Neck Neoplasms	3	CTD_human
Hgene	EGFR	C0027627	Neoplasm Metastasis	3	CTD_human
Hgene	EGFR	C0033578	Prostatic Neoplasms	3	CTD_human
Hgene	EGFR	C0038356	Stomach Neoplasms	3	CTD_human
Hgene	EGFR	C0278996	Malignant Head and Neck Neoplasm	3	CGI;CTD_human
Hgene	EGFR	C0376358	Malignant neoplasm of prostate	3	CTD_human
Hgene	EGFR	C0546837	Malignant neoplasm of esophagus	3	CGI;CTD_human
Hgene	EGFR	C0746787	Cancer of Neck	3	CTD_human
Hgene	EGFR	C0751177	Cancer of Head	3	CTD_human
Hgene	EGFR	C0887900	Upper Aerodigestive Tract Neoplasms	3	CTD_human
Hgene	EGFR	C1621958	Glioblastoma Multiforme	3	CTD_human
Hgene	EGFR	C1708349	Hereditary Diffuse Gastric Cancer	3	CTD_human
Hgene	EGFR	C4048328	cervical cancer	3	CTD_human
Hgene	EGFR	C0005684	Malignant neoplasm of urinary bladder	2	CTD_human
Hgene	EGFR	C0005695	Bladder Neoplasm	2	CTD_human
Hgene	EGFR	C0007102	Malignant tumor of colon	2	CTD_human
Hgene	EGFR	C0009375	Colonic Neoplasms	2	CTD_human
Hgene	EGFR	C0009402	Colorectal Carcinoma	2	CTD_human
Hgene	EGFR	C0009404	Colorectal Neoplasms	2	CTD_human
Hgene	EGFR	C0024668	Mammary Neoplasms, Experimental	2	CTD_human
Hgene	EGFR	C0027626	Neoplasm Invasiveness	2	CTD_human
Hgene	EGFR	C0027643	Neoplasm Recurrence, Local	2	CTD_human
Hgene	EGFR	C0152013	Adenocarcinoma of lung (disorder)	2	CGI;CTD_human
Hgene	EGFR	C0206726	gliosarcoma	2	ORPHANET
Hgene	EGFR	C0919267	ovarian neoplasm	2	CTD_human
Hgene	EGFR	C1140680	Malignant neoplasm of ovary	2	CTD_human
Hgene	EGFR	C4015130	INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2	2	CTD_human;GENOMICS_ENGLAND;UNIPROT
Hgene	EGFR	C0001973	Alcoholic Intoxication, Chronic	1	PSYGENET
Hgene	EGFR	C0003865	Arthritis, Adjuvant-Induced	1	CTD_human
Hgene	EGFR	C0005396	Bile Duct Neoplasms	1	CTD_human
Hgene	EGFR	C0007097	Carcinoma	1	CTD_human
Hgene	EGFR	C0007113	Rectal Carcinoma	1	CTD_human
Hgene	EGFR	C0007193	Cardiomyopathy, Dilated	1	CTD_human
Hgene	EGFR	C0011603	Dermatitis	1	CTD_human
Hgene	EGFR	C0011860	Diabetes Mellitus, Non-Insulin-Dependent	1	CTD_human
Hgene	EGFR	C0014175	Endometriosis	1	CTD_human
Hgene	EGFR	C0016978	gallbladder neoplasm	1	CTD_human
Hgene	EGFR	C0021655	Insulin Resistance	1	CTD_human
Hgene	EGFR	C0022660	Kidney Failure, Acute	1	CTD_human
Hgene	EGFR	C0024667	Animal Mammary Neoplasms	1	CTD_human
Hgene	EGFR	C0024809	Marijuana Abuse	1	PSYGENET
Hgene	EGFR	C0025500	Mesothelioma	1	CTD_human
Hgene	EGFR	C0027439	Nasopharyngeal Neoplasms	1	CTD_human
Hgene	EGFR	C0029463	Osteosarcoma	1	CTD_human
Hgene	EGFR	C0030297	Pancreatic Neoplasm	1	CTD_human
Hgene	EGFR	C0030354	Papilloma	1	CTD_human
Hgene	EGFR	C0032580	Adenomatous Polyposis Coli	1	CTD_human
Hgene	EGFR	C0034885	Rectal Neoplasms	1	CTD_human
Hgene	EGFR	C0041696	Unipolar Depression	1	PSYGENET
Hgene	EGFR	C0085548	Autosomal Recessive Polycystic Kidney Disease	1	CTD_human
Hgene	EGFR	C0085762	Alcohol abuse	1	PSYGENET
Hgene	EGFR	C0149925	Small cell carcinoma of lung	1	CTD_human
Hgene	EGFR	C0153452	Malignant neoplasm of gallbladder	1	CTD_human
Hgene	EGFR	C0205696	Anaplastic carcinoma	1	CTD_human
Hgene	EGFR	C0205697	Carcinoma, Spindle-Cell	1	CTD_human
Hgene	EGFR	C0205698	Undifferentiated carcinoma	1	CTD_human
Hgene	EGFR	C0205699	Carcinomatosis	1	CTD_human
Hgene	EGFR	C0205874	Papilloma, Squamous Cell	1	CTD_human
Hgene	EGFR	C0205875	Papillomatosis	1	CTD_human
Hgene	EGFR	C0206686	Adrenocortical carcinoma	1	CTD_human
Hgene	EGFR	C0206698	Cholangiocarcinoma	1	CTD_human
Hgene	EGFR	C0235874	Disease Exacerbation	1	CTD_human
Hgene	EGFR	C0238301	Cancer of Nasopharynx	1	CTD_human
Hgene	EGFR	C0263454	Chloracne	1	CTD_human
Hgene	EGFR	C0269102	Endometrioma	1	CTD_human
Hgene	EGFR	C0279626	Squamous cell carcinoma of esophagus	1	CGI;CTD_human
Hgene	EGFR	C0345905	Intrahepatic Cholangiocarcinoma	1	CTD_human
Hgene	EGFR	C0345967	Malignant mesothelioma	1	CTD_human
Hgene	EGFR	C0346647	Malignant neoplasm of pancreas	1	CTD_human
Hgene	EGFR	C0376634	Craniofacial Abnormalities	1	CTD_human
Hgene	EGFR	C0740277	Bile duct carcinoma	1	CTD_human
Hgene	EGFR	C0920563	Insulin Sensitivity	1	CTD_human
Hgene	EGFR	C0971858	Arthritis, Collagen-Induced	1	CTD_human
Hgene	EGFR	C0993582	Arthritis, Experimental	1	CTD_human
Hgene	EGFR	C1257925	Mammary Carcinoma, Animal	1	CTD_human
Hgene	EGFR	C1269683	Major Depressive Disorder	1	PSYGENET
Hgene	EGFR	C1449563	Cardiomyopathy, Familial Idiopathic	1	CTD_human
Hgene	EGFR	C1565662	Acute Kidney Insufficiency	1	CTD_human
Hgene	EGFR	C2239176	Liver carcinoma	1	CTD_human
Hgene	EGFR	C2609414	Acute kidney injury	1	CTD_human
Hgene	EGFR	C2713442	Polyposis, Adenomatous Intestinal	1	CTD_human
Hgene	EGFR	C2713443	Familial Intestinal Polyposis	1	CTD_human
Hgene	EGFR	C3805278	Extrahepatic Cholangiocarcinoma	1	CTD_human
Hgene	EGFR	C4751120	Neonatal inflammatory skin and bowel disease	1	ORPHANET